| Name | Blebbistatin |
| Description | Blebbistatin ((±)-Blebbistatin) is a non-muscle myosin II (NMII)-selective and non-muscle myosin heavy chain 9 (MYH9)-specific inhibitor that promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, while preserving the integrity of cell junctions and barrier function. |
| In vitro | Blebbistatin is a cell-permeable non-muscle myosin II ATPases inhibitor with an IC50 range of 2 μM. |
| In vivo | METHODS: Blebbistatin ((±)-Blebbistatin) (10, 20, 40 mg/kg, intraperitoneal injection, once every two days, 4 weeks) was administered to NCl-H460 model nude mice, and the changes in tumors in the mice were observed.
RESULTS The inhibition rates of Blebbistatin ((±)-Blebbistatin) on xenograft tumor weight were 23.4%, 40.2%, and 83.4%, respectively. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 23 mg/mL (78.68 mM), Sonication is recommended.
|
| Keywords | non-muscle myosin II ATPases | Myosin | Inhibitor | inhibit | Blebbistatin |
| Inhibitors Related | Mavacamten | Sodium oleate | Permethrin | Tolbutamide | trans-Aconitic acid | Phlorizin | Chlorpropamide | 2,3-Butanedione 2-Monoxime | 4-Hydroxyacetophenone | Revaprazan hydrochloride | Oleic acid | Cyclocreatine |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Multi-Target Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library | Human Metabolite Library |
United States
